Navigation Links
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Date:5/30/2009

rs of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN inhibitors. The Company has successfully discovered and is developing a portfolio of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information visit the Company's web site at www.SemaforePharma.com.


'/>"/>
SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
3. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
4. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
5. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
6. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
7. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
8. Cardiologists Tackle Next Frontier in Cardiovascular Disease
9. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
10. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014  The objective of this market insight ... and research facilities across North America ... study carries out an assessment of the current and ... and law enforcement forensics labs. It also provides a ... PPE segments, and safety regulations specific to labs and ...
(Date:9/23/2014)... PARIS , September 23, 2014 /PRNewswire/ ... tels que l,automobile, la santé, le ferroviaire ... en plus connectées, donneront progressivement accès à ... issues des nombreux capteurs installés au cœur ... estime à plusieurs dizaines de milliards le ...
(Date:9/23/2014)... Sept. 23, 2014 Research and ... "Physician Office Laboratory Markets, 3rd Edition" ... report, Physician Office Laboratory Markets is Kalorama,s complete ... industry. Physician office laboratories are diverse in their ... reimbursable, in-office pregnancy and glucose tests. Some specialty ...
Breaking Medicine Technology:Personal Protective Equipment (PPE) Outlook for the North American and Western European Labs and Research Facilities 2Personal Protective Equipment (PPE) Outlook for the North American and Western European Labs and Research Facilities 3Altran transforme le big data du monde industriel en nouveau business 2Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 Oaksterdam University ... Today . In its first post, the University addresses ... and changing cannabis industry. , The cannabis industry is ... alone is expecting an 18-month boost of more than ... adult use pot sales. And, the new legal recreational ...
(Date:9/23/2014)... NIH TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF ... WHAT: , The National Institutes of Health is ... available scientific evidence on the long-term effectiveness and potential ... be among the nation,s top experts in the field ... as well as key NIH scientists who focus on ...
(Date:9/23/2014)... 2014 As a consumer in today’s ... purchase. It’s difficult to trust testimonials that are supplied ... to manipulate their customers into saying anything. , Consumer ... tend to lack in depth coverage on a particular ... founded to fix this issue and focus on exposing ...
(Date:9/23/2014)... Sept. 23, 2014 (HealthDay News) -- Both drinking and ... factors for alcohol abuse by high school students, a ... survey of high school students who drink, could help ... who already drink, to stop them from becoming binge ... between age of first alcohol use and progression to ...
(Date:9/23/2014)... 23, 2014 What: Rutgers Presbyterian ... West Side that embodies the inclusion and diversity ... Scripture and the Ecological Crisis, a public lecture ... Professor Emerita of Old Testament at Louisville Presbyterian ... wisdom that lends insight into current ecological problems, ...
Breaking Medicine News(10 mins):Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2
... Annual and Special Meeting web cast live, LAVAL, ... Special,meeting of Neurochem Inc. (NASDAQ: NRMX ; TSX: ... new name, BELLUS Health Inc., which,it expects to start ... stock,ticker symbols (NASDAQ: BLUS ; TSX: BLU). Neurochem ...
... 15 Heritage Pharma Ltd.,(U.K.) and its wholly ... the Company has consummated the,private placement of Series ... capital investors McClendon Venture Company, LLC and,TLW Venture ... prior to fees,and expenses. The proceeds will be ...
... a high frequency of sleep-related breathing disorders (SRBD) in ... an overnight sleep test, especially in patients with underlying ... April 15 issue of the Journal of Clinical Sleep ... MD, of Johns Hopkins University and Bayview Medical Center ...
... Allergies and asthma affect,six times more Americans than ... America. As the fifth leading chronic disease, allergies,along ... Americans., (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/NYTUFNS1 ), ... to prevent or treat,allergies and asthma," said Peggy ...
... therapy shows promise against pancreatic tumors, scientists say , , ... drug duo might help prevent colorectal cancer, and the ... of liver cancer. , So conclude two studies presented ... meeting in San Diego. , In the first report, ...
... Position Company to Meet Strategic ... Growth Objectives, ... global full-service clinical research organization, today,announced the promotion of Simon S. ... as President and Chief Operating,Officer, will continue as Chief Operating Officer. ...
Cached Medicine News:Health News:At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM) 2Health News:At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM) 3Health News:At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM) 4Health News:At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM) 5Health News:At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM) 6Health News:Heritage Announces $10 Million Financing 2Health News:JCSM: A high frequency of sleep-related breathing disorders in hospitalized patients 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 5Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 6Health News:New Treatments Help Fight Liver, Colon Cancer 2Health News:New Treatments Help Fight Liver, Colon Cancer 3Health News:New Treatments Help Fight Liver, Colon Cancer 4Health News:Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer 2Health News:Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer 3
Indicated for procedures of the wrist, ankle, elbow, and other small joints, the,UltrAblator is effective for ablation of soft tissue and coagulation of bleeders,encountered during surgery....
... This implant is designed to replace the ... on the distal pole which fits under a ... bone, and a suture hole on the proximal ... anatomical position during the early postoperative period until ...
... has the same anatomical configuration as the ... to provide for stability. The implant has ... use in suture fixation through the scaphoid ... while a capsuloligamentous system forms around the ...
... for four corner fusion of the capitate, ... hand. The plate is intended for use ... of function due to SLAC and SNAC ... rheumatoid arthritis. When combined with the specially ...
Medicine Products: